2023-05-21 21:21:58
The drug price of AbbVie Korea’s Rinvoq sustained-release tablet (Eupadacitinib), used for the treatment of rheumatoid arthritis, and Gilead Sciences’ Vemlidi tablet (Temofovir alafenamide), used for the treatment of chronic hepatitis B infection, will be reduced from the 1st of next month. .
It is the result that the drug price has become a subject of follow-up management because it sold a lot.
According to related industries on the 21st, two drugs, Rinvoq sustained-release tablet 15mg and Vemlidi tablet, are subject to the volume-price negotiation (PVA) and the upper limit is adjusted on June 1st.
Rinvoq sustained-release tablet 15mg was subject to the ‘type price’, and price adjustment negotiations were held between the Health Insurance Corporation and AbbVie. ‘Type price’ is applied when the billing amount for the same product group increases by more than 30% from the expected billing amount for drug price negotiations. However, as a result of the negotiations, the rate of reduction of the upper limit was 0.89%, less than 1%. Specifically, it is adjusted from 20,010 won to 19,831 won.
Vemlidy Chung received the ‘type or type’ negotiation type. The upper limit amount was adjusted by ‘type price’, or the claim amount of the same product category after 4 years from the date of initial listing without negotiation of ‘type price’ or the date when the upper limit amount was adjusted through negotiation is 60% or more or 10% of the claim amount of the previous year If the increase is greater than 5 billion won, it is eligible.
As a result of the negotiations, the NHIS and Gilead agreed on a 4.67% reduction rate. Accordingly, the upper limit for Vemlidy Tablet will be adjusted from 3,535 won to 3,370 won from June 1.
1684707713
#Rinvoq #sustainedrelease #tablets #Vemlidy #tablets #sold #lot #drug #prices #cut…From #June #1st